Inovio Pharma (INO)
$8.40
0.03 (0.35%)
INO Stock Quote Delayed 30 Minutes
Inovio Becomes a Covid-19 Longshot
No one knows which of the many vaccine candidates will be safe and effective, but Inovio's unique approach has left it without a major manufacturing contract.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.77B
PE Ratio
-1.16
EPS
-7.24
Volume (Avg. Vol.)
21,357
Day's Range
$8.36 - $8.58
52-Week Range
$0.32 - $14.75
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Inovio Still Has a Chance to Break Out in a Big Way
Inovio did not get the government funding or pre-orders like its competitors did, so if it happens later, INO stock will respond positively
It’s Time to Get Serious About Inovio Pharmaceuticals
Due to the government's desire to develop multiple vaccine candidates and several intriguing catalysts, INO stock deserves serious consideration.
What the Charts Say for Inovio Stock Right Now
Inovio stock will live and die by its coronavirus vaccine results. However, INO stock continues to trade well, with a solid chart setup.
Hold Off Buying The Dip in Pandemic Play Inovio Stock
So, what's the verdict? Stay on the sidelines with INO stock for now, but consider shares if they continue falling back to lower prices.
It’s Warp Speed Ahead Now for Inovio
Inclusion in a government program to fight the spread of the coronavirus is a major catalyst event for INO stock.
Don’t Count on Inovio To Deliver a Covid-19 Vaccine
While there is a lot to like about INO stock, investors who are counting on the company to cure Covid-19 may be delusional.
3 Reasons to Sell Inovio Stock
Inovio has made advances towards developing a coronavirus vaccine. However, now isn't the time to invest in INO stock.
Whatever Happens to Inovio Pharmaceuticals, Insiders Will Do Just Fine
Inovio Pharmaceuticals' (NASDAQ:INO) insiders are benefitting from the novel coronavirus and the rise of INO stock.
Inovio Is Too Risky for the Average Investor
With the likelihood of a coronavirus vaccine still largely unknown, betting on INO stock based on its vaccine candidate is too risky.
Why Novavax Stock is Still a Strong Buy Even After an 800% Move
While NVAX stock could race higher on news in coming days of its clinical trials results, play this one safe with a trailing stop loss to safeguard any wins you have to date.
The Further It Lags in the Vaccine Race, the Riskier Inovio Stock Looks
Inovio Pharmaceuticals (NASDAQ:INO) is a contender in the hyper-competitive field to develop a novel coronavirus vaccine, but with the company falling behind rivals, INO stock…
History and Competition Suggest Caution Toward Inovio Stock
INO stock has rallied more than 700% so far this year. But the company needs to succeed where it has failed in the past and beat rivals in the process.
The Curtain Is Coming Down on Inovio Pharmaceuticals’ Vaccine Candidate
As multiple companies advance vaccine candidates into late-stage clinical trials, INO stock is losing momentum. Is this the end or just a pause?
4 Catalysts Could Drive Inovio Pharmaceuticals Stock to Near-term Highs
Inovio Pharmaceuticals remains one of the most undervalued of the vaccine makers. Even after a 455% run higher, INO stock has plenty of upside fueled by plenty of catalysts.
Inovio May Be Losing the Covid-19 Vaccine Race
Moderna and AstraZeneca both are making rapid progress on their coronavirus vaccines. For Inovio, this means that the clock is ticking down.
It Looks Like Inovio Stock May Still Be Set up for an Explosive Rally
Inovio has been on fire, and while its catalyst is tied to the coronavirus, the charts remain bullish. Let's look more closely at INO stock.
4 Top Stock Trades for Wednesday: JPM, DAL, FAST, INO
Fastenal, Delta Air Lines, Inovio and JPMorgan were our top stock trades for Wednesday. That said, let's look at the charts moving forward.
How the U.S. Constitution Is Helping Inovio Pharmaceuticals
INO stock has transformed this year from unknown to a Wall Street darling. But with a worsening pandemic, the long-term case for Inovio has become even more credible.
Is It Finally Time to Buy INO Stock?
The world wants a Covid-19 vaccine, but for investors trying to improve the health of their portfolio, the only way to immunize properly in upstart Inovio is with this options strategy
